Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-7505
- Development stage
- Preclinical
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
01
Overview
DA-7505 is a small molecule therapeutic candidate currently in the preclinical stage of development by the South Korean pharmaceutical company **Dong-A ST**. The asset is being investigated for its potential application in treating both **inflammatory diseases** and **neurodegenerative diseases**. As of the current reporting, the specific biological target and mechanism of action for DA-7505 remain proprietary and have not been publicly disclosed. The drug is part of Dong-A ST's broader research and development strategy focused on addressing conditions characterized by chronic inflammation and neuronal damage, where there is a significant unmet medical need.
Beyond the preview
Go deeper on DA-7505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-7505.